公司資料
Enliven Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ELVN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
59.82 USD (+1.53%)
收盤價
最後更新: 2026年8月21日
2.16B USD
市值
股價為何變動
As of Aug 21, 2026, ELVN closed up 1.53% at $59.82. No new same-company headline was identified in the current news window.
公司概覽
Precision Oncology
Enliven Therapeutics develops small-molecule precision medicines intended to improve both survival and quality of life for people with cancer.
ELVN-001
ELVN-001 is a selective BCR::ABL1 tyrosine-kinase inhibitor for chronic myeloid leukemia. It is designed to retain antileukemic activity while reducing off-target effects associated with existing therapies.
Late-Stage Development Path
Clinical development is moving from Phase 1 evaluation toward the pivotal ENABLE-2 program, positioning ELVN-001 as the company's principal potential registrational asset.
未來催化劑
- Phase 1 data update for ELVN-001 around mid-2026.
- Initiation of the Phase 3 ENABLE-2 trial in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。